Cargando…
Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience
INTRODUCTION: Hepatitis C virus (HCV) infection has detrimental effects on patient and graft survival after kidney transplantation. In the pre‐direct‐acting antiviral (DAA) era, treatment of HCV infection was associated with low response rates, poor tolerance, and increased risk of allograft rejecti...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860605/ https://www.ncbi.nlm.nih.gov/pubmed/33264509 http://dx.doi.org/10.1002/iid3.386 |
_version_ | 1783646913104445440 |
---|---|
author | Alkadi, Mohamad M. Abuhelaiqa, Essa A. Elshirbeny, Mostafa F. Hamdi, Ahmed F. Fituri, Omar M. Asim, Muhammad Alkaabi, Saad R. Derbala, Moutaz F. Jarman, Mona E. Ashour, Adel M. Nauman, Awais Al Maslamani, Yousuf K. Butt, Adeel A. Al‐Malki, Hassan A. |
author_facet | Alkadi, Mohamad M. Abuhelaiqa, Essa A. Elshirbeny, Mostafa F. Hamdi, Ahmed F. Fituri, Omar M. Asim, Muhammad Alkaabi, Saad R. Derbala, Moutaz F. Jarman, Mona E. Ashour, Adel M. Nauman, Awais Al Maslamani, Yousuf K. Butt, Adeel A. Al‐Malki, Hassan A. |
author_sort | Alkadi, Mohamad M. |
collection | PubMed |
description | INTRODUCTION: Hepatitis C virus (HCV) infection has detrimental effects on patient and graft survival after kidney transplantation. In the pre‐direct‐acting antiviral (DAA) era, treatment of HCV infection was associated with low response rates, poor tolerance, and increased risk of allograft rejection. However, DAAs have revolutionized HCV treatment. The aims of this study were to determine the impact of DAA on the sustained virologic response (SVR), renal function, and calcineurin inhibitor (CNI) levels and assess the tolerability to treatment in kidney transplant recipients with HCV infection in Qatar. METHODS: This retrospective study included the medical records of all kidney transplant recipients with confirmed HCV infection before January 1, 2020. All data were obtained from the patients’ electronic medical records; these included patient demographics; virologic responses to treatment; serum creatinine levels during treatment; urine protein to creatinine ratios and CNI levels before, during, and after treatment; and side effects related to DAA therapy. RESULTS: A total of 27 kidney transplant recipients with HCV were identified, 23 of whom received DAA therapy. The length of treatment ranged from 12 to 24 weeks, and 52% of patients had HCV genotype 1 infection. The median log10 HCV RNA was 6.6 copies per milliliter. None of the patients had liver cirrhosis, and all of them achieved SVR. There was no statistically significant difference in the glomerular filtration rate before, during, and after treatment. Most patients had stable CNI trough levels during treatment and did not require dose adjustment. CONCLUSIONS: HCV infection was successfully eradicated by DAA therapy in kidney transplant recipients, with a 100% SVR rate. Moreover, DAA therapy was well‐tolerated, and kidney function remained stable without an increased risk of rejection. These results are expected to drive the eradication of hepatitis C from the entire country. |
format | Online Article Text |
id | pubmed-7860605 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78606052021-02-05 Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience Alkadi, Mohamad M. Abuhelaiqa, Essa A. Elshirbeny, Mostafa F. Hamdi, Ahmed F. Fituri, Omar M. Asim, Muhammad Alkaabi, Saad R. Derbala, Moutaz F. Jarman, Mona E. Ashour, Adel M. Nauman, Awais Al Maslamani, Yousuf K. Butt, Adeel A. Al‐Malki, Hassan A. Immun Inflamm Dis Original Research INTRODUCTION: Hepatitis C virus (HCV) infection has detrimental effects on patient and graft survival after kidney transplantation. In the pre‐direct‐acting antiviral (DAA) era, treatment of HCV infection was associated with low response rates, poor tolerance, and increased risk of allograft rejection. However, DAAs have revolutionized HCV treatment. The aims of this study were to determine the impact of DAA on the sustained virologic response (SVR), renal function, and calcineurin inhibitor (CNI) levels and assess the tolerability to treatment in kidney transplant recipients with HCV infection in Qatar. METHODS: This retrospective study included the medical records of all kidney transplant recipients with confirmed HCV infection before January 1, 2020. All data were obtained from the patients’ electronic medical records; these included patient demographics; virologic responses to treatment; serum creatinine levels during treatment; urine protein to creatinine ratios and CNI levels before, during, and after treatment; and side effects related to DAA therapy. RESULTS: A total of 27 kidney transplant recipients with HCV were identified, 23 of whom received DAA therapy. The length of treatment ranged from 12 to 24 weeks, and 52% of patients had HCV genotype 1 infection. The median log10 HCV RNA was 6.6 copies per milliliter. None of the patients had liver cirrhosis, and all of them achieved SVR. There was no statistically significant difference in the glomerular filtration rate before, during, and after treatment. Most patients had stable CNI trough levels during treatment and did not require dose adjustment. CONCLUSIONS: HCV infection was successfully eradicated by DAA therapy in kidney transplant recipients, with a 100% SVR rate. Moreover, DAA therapy was well‐tolerated, and kidney function remained stable without an increased risk of rejection. These results are expected to drive the eradication of hepatitis C from the entire country. John Wiley and Sons Inc. 2020-12-02 /pmc/articles/PMC7860605/ /pubmed/33264509 http://dx.doi.org/10.1002/iid3.386 Text en © 2020 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Alkadi, Mohamad M. Abuhelaiqa, Essa A. Elshirbeny, Mostafa F. Hamdi, Ahmed F. Fituri, Omar M. Asim, Muhammad Alkaabi, Saad R. Derbala, Moutaz F. Jarman, Mona E. Ashour, Adel M. Nauman, Awais Al Maslamani, Yousuf K. Butt, Adeel A. Al‐Malki, Hassan A. Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience |
title | Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience |
title_full | Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience |
title_fullStr | Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience |
title_full_unstemmed | Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience |
title_short | Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience |
title_sort | eradication of hepatitis c virus infection in kidney transplant recipients using direct‐acting antiviral therapy: qatar experience |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860605/ https://www.ncbi.nlm.nih.gov/pubmed/33264509 http://dx.doi.org/10.1002/iid3.386 |
work_keys_str_mv | AT alkadimohamadm eradicationofhepatitiscvirusinfectioninkidneytransplantrecipientsusingdirectactingantiviraltherapyqatarexperience AT abuhelaiqaessaa eradicationofhepatitiscvirusinfectioninkidneytransplantrecipientsusingdirectactingantiviraltherapyqatarexperience AT elshirbenymostafaf eradicationofhepatitiscvirusinfectioninkidneytransplantrecipientsusingdirectactingantiviraltherapyqatarexperience AT hamdiahmedf eradicationofhepatitiscvirusinfectioninkidneytransplantrecipientsusingdirectactingantiviraltherapyqatarexperience AT fituriomarm eradicationofhepatitiscvirusinfectioninkidneytransplantrecipientsusingdirectactingantiviraltherapyqatarexperience AT asimmuhammad eradicationofhepatitiscvirusinfectioninkidneytransplantrecipientsusingdirectactingantiviraltherapyqatarexperience AT alkaabisaadr eradicationofhepatitiscvirusinfectioninkidneytransplantrecipientsusingdirectactingantiviraltherapyqatarexperience AT derbalamoutazf eradicationofhepatitiscvirusinfectioninkidneytransplantrecipientsusingdirectactingantiviraltherapyqatarexperience AT jarmanmonae eradicationofhepatitiscvirusinfectioninkidneytransplantrecipientsusingdirectactingantiviraltherapyqatarexperience AT ashouradelm eradicationofhepatitiscvirusinfectioninkidneytransplantrecipientsusingdirectactingantiviraltherapyqatarexperience AT naumanawais eradicationofhepatitiscvirusinfectioninkidneytransplantrecipientsusingdirectactingantiviraltherapyqatarexperience AT almaslamaniyousufk eradicationofhepatitiscvirusinfectioninkidneytransplantrecipientsusingdirectactingantiviraltherapyqatarexperience AT buttadeela eradicationofhepatitiscvirusinfectioninkidneytransplantrecipientsusingdirectactingantiviraltherapyqatarexperience AT almalkihassana eradicationofhepatitiscvirusinfectioninkidneytransplantrecipientsusingdirectactingantiviraltherapyqatarexperience |